Johnson & Johnson (JNJ) Stock Could Win BIG After Actelion Purchase

JNJ stock could see a boost in the long-term: Johnson & Johnson is paying $30 billion for Actelion, a Swiss maker of hypertension drugs, then spinning off its research unit to Actelion's founders. More 

Markets Hit All-Time Highs on $1 Trillion Infrastructure Plan

In the stock market, the Dow wafted up 0.6%, the S&P 500 moved up 0.6%, the Nasdaq gained 0.8%% and the Russell 2000 ended 1.6% higher. More 

3 Stocks to Watch on Tuesday: Apple Inc. (AAPL), Verizon Communications Inc. (VZ) and Johnson & Johnson (JNJ)

Verizon (VZ) and Johnson & Johnson (JNJ) are dipping after their quarterly reports, while Apple (AAPL) suffers another downgrade. More 

10 Blue-Chip Stocks That Could Be Holding You Back

These 10 widely held blue-chip stocks are dangerously valued, and every one of them should be dealt with -- in different ways -- right away. More 

5 Trump-Proof Pharma Dividend Stocks to Buy

Pharma is under the proverbial gun as Trump takes office, but these pharma dividend payers are stocks to buy for the long term More 

As Calpers Flails, Don’t Bank on Your Pension

Calpers is just one of many underfunded pension funds. Use your savings to invest to supplement retirement income. More 

17 Quality Dividend Stocks For 2017 and Beyond

Looking out over the landscape of dividend stocks, I've picked out these as attractively valued and worth consideration to buy More